

Policies Repository



Policy Title Rufinamide (Banzel™)

Policy Number FS.CLIN.69

Application of Pharmacy Policy is determined by benefits and contracts. Benefits may vary based on product line, group or contract. Some medications may be subject to precertification, age, gender or quantity edits. Individual member benefits must be verified.

This Pharmacy Policy document describes the status of pharmaceutical information and/or technology at the time the document was developed. Since that time, new information relating to drug efficacy, interactions, contraindications, dosage, administration routes, safety or FDA approval may have changed. If the Medical/Pharmacy Reviewer is aware of any new information on the subject of this document, please provide it promptly to the Medical/Pharmacy Policy Department. This information may include new FDA approved indications, withdrawals or other FDA alerts. This type of information is relevant not only when considering whether this Policy should be updated, but also when applying it to current requests for coverage.

Members are advised to use participating pharmacies in order to receive the highest level of benefits.

Policy **Rufinamide (Banzel™)** is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in adults and children 4 years of age and older.

The use of rufinamide (Banzel™) requires prior authorization (ie, clinical pharmacy and/or Medical Director review).

Policy Description **Rufinamide (Banzel™)** is an anticonvulsant. While the precise mechanism(s) by which rufinamide exerts its antiepileptic effect is unknown, it is thought that as per invitro studies that it modulates the activity of sodium channels and then prolongs the inactive state of the channel.

Policy Guideline Inclusion **Rufinamide tablets (Banzel™)** is approved when the following inclusion criterion is met:

- Documentation of diagnosis of seizures associated with Lennox-Gastaut syndrome

Policy Guideline Exclusion **Rufinamide tablets (Banzel™)** is denied when the following exclusion criterion is found:

- No documentation of diagnosis of seizures associated with Lennox-Gastaut syndrome

Policy List of Applicable Drugs

| Brand Name | Generic Name |
|------------|--------------|
| Banzel | Rufinamide |

Dosing and Administration Refer to the specific manufacturer's prescribing information for administration and dosage details for each specific agent.

Policy References

Banzel™ (rufinamide). In: Facts and Comparisons [online through Facts and Comparisons Online]. Indy, IN: Walter Kluwer Health Inc. Accessed February 12, 2009.

Banzel™ (rufinamide). In: Drugdex [online through Micromedex Healthcare Series]. Greenwood Village, CO: Thomson Micromedex. Accessed February 12, 2009.

Banzel™ (rufinamide). Woodcliff Lake, NJ; Novartis Pharma AG: November 2008.

Policy Link to Related Policies

Printed

07/06/2009 09:32:08

The Policy Bulletins on this web site were developed to assist Independence Blue Cross and its subsidiaries ("IBC") in administering the provisions of the respective benefit programs, and do not constitute a contract. If you are an IBC member, please refer to your specific benefit program for the terms, conditions, limitations and exclusions of your coverage. IBC does not provide health care services, medical advice or treatment, or guarantee the outcome or results of any medical services/treatments. The facility and professional providers are responsible for providing medical advice and treatment. Facility and professional providers are independent contractors and are not employees or agents of IBC. If you have a specific medical condition, please consult with your doctor. IBC reserves the right at any time to change or update its Policy Bulletins. © 2008 Independence Blue Cross. All Rights Reserved. Current Procedural Terminology © 2008 American Medical Association. All Rights Reserved.

|